(19)
(11) EP 1 436 290 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.12.2013 Bulletin 2013/49

(45) Mention of the grant of the patent:
18.09.2013 Bulletin 2013/38

(21) Application number: 02754079.8

(22) Date of filing: 27.08.2002
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61K 31/435(2006.01)
 C07D 519/00(2006.01)
(86) International application number:
PCT/CA2002/001324
(87) International publication number:
WO 2003/018579 (06.03.2003 Gazette 2003/10)

(54)

ALKYNE-ARYL-NAPHTHYRIDIN-4(1H)-0NE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITOR

ALKYNE-ARYL-NAPHTHYRIDIN-4(1H)-0NE DERIVATE ALS HEMMER VON PHOSPHODIESTERASE DES TYPS IV

DERIVES D'ALKYNE-ARYLE-NAPHTHYRIDINE-4-ONE (1H) TENANT LIEU D'INHIBITEURS DE PHOSPHODIESTERASE-4

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 29.08.2001 US 316093 P

(43) Date of publication of application:
14.07.2004 Bulletin 2004/29

(60) Divisional application:
10191086.7 / 2305677

(73) Proprietor: Merck Canada Inc.
Kirkland QC H9H 3L1 (CA)

(72) Inventors:
  • GUAY, Daniel
    Kirkland, Québec H9H 3L1 (CA)
  • GIRARD, Mario
    Kirkland, Québec H9H 3L1 (CA)
  • HAMEL, Pierre
    Kirkland, Québec H9H 3L1 (CA)
  • LALIBERTE, Sebastien
    Kirkland, Québec H9H 3L1 (CA)
  • FRIESEN, Richard
    Kirkland, Québec H9H 3L1 (CA)

(74) Representative: Buchan, Gavin MacNicol et al
Merck Sharp & Dohme Limited European Patent Department Hertford Road
Hoddesdon Hertfordshire EN11 9BU
Hoddesdon Hertfordshire EN11 9BU (GB)


(56) References cited: : 
EP-A- 0 978 516
WO-A-99/07704
 WO-A-00/09504
   
  • MATSUURA A ET AL: "Substituted 1,8-Naphthyridin-281H)-ones as Selective Phosphodiesterase IV Inhibitors" BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 17, no. 4, 1 April 1994 (1994-04-01), pages 498-503, XP002084207 ISSN: 0918-6158
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).